GLP1R and metabolic dysfunction-associated steatohepatitis: Our study demonstrated that BS was significantly associated with a lower incidence of new‐onset NASH compared to GLP‐1 RA therapy, with a hazard ratio (HR) of 0.509 (95% CI, 0.469–0.551).